Andrew M Heitzer1, Jason M Ashford1, Camden Hastings2, Anthony P Y Liu3, Shengjie Wu4, Johnnie K Bass5, Robert Vestal6, Mary Hoehn3,6,7, Jason Chiang8, Yahya Ghazwani3, Sahaja Acharya9, Frederick Boop7,10,11,12, Amar Gajjar3, Thomas E Merchant9, Ibrahim Qaddoumi3, Heather M Conklin13. 1. Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. 2. Pediatric Oncology Education Program, St. Jude Children's Research Hospital, Memphis, TN, USA. 3. Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 4. Department of Biostatistics, St. Jude Children's Research Hospital, Memphis, TN, USA. 5. Rehabilitation Services, St. Jude Children's Research Hospital, Memphis, TN, USA. 6. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, TN, USA. 7. Department of Surgery, St. Jude Children's Research Hospital, Memphis, TN, USA. 8. Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA. 9. Department of Radiation Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA. 10. Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, TN, USA. 11. Le Bonheur Neuroscience Institute, Le Bonheur Children's Hospital, Memphis, TN, USA. 12. Semmes Murphey Clinic, Memphis, TN, USA. 13. Department of Psychology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, Memphis, TN, 38105-2794, USA. heather.conklin@stjude.org.
Abstract
PURPOSE: Low-grade gliomas (LGG) are a heterogeneous group of brain tumors, which are often assumed to have a benign course. Yet, children diagnosed and treated for LGG in infancy are at increased risk for neurodevelopmental disruption. We sought to investigate neuropsychological outcomes of infants diagnosed with LGG. METHODS: Between 1986 and 2013, 51 patients were diagnosed with LGG before 12 months of age and managed at St. Jude Children's Research Hospital. Twenty-five of the 51 patients received a cognitive assessment (68% male; 6.8 ± 3.3 months at diagnosis; 10.5 ± 4.8 years at latest assessment). Approximately half the patients received radiation therapy (n = 12; aged 4.0 ± 3.0 years at radiation therapy), with a median of 2 chemotherapy regimens (range = 0-5) and 1 tumor directed surgery (range = 0-5). RESULTS: The analyses revealed performance below age expectations on measures of IQ, memory, reading, mathematics, and fine motor functioning as well as parent-report of attention, executive, and adaptive functioning. Following correction for multiple comparisons, a greater number of chemotherapy regimens was associated with lower scores on measures of IQ and mathematics. More tumor directed surgeries and presence of visual field loss were associated with poorer dominant hand fine motor control. Radiation therapy exposure was not associated with decline in neuropsychological performance. CONCLUSIONS: Children diagnosed with LGG in infancy experience substantial neuropsychological deficits. Treatment factors, including number of chemotherapy regimens and tumor directed surgeries, may increase risk for neurodevelopmental disruption and need to be considered in treatment planning.
PURPOSE: Low-grade gliomas (LGG) are a heterogeneous group of brain tumors, which are often assumed to have a benign course. Yet, children diagnosed and treated for LGG in infancy are at increased risk for neurodevelopmental disruption. We sought to investigate neuropsychological outcomes of infants diagnosed with LGG. METHODS: Between 1986 and 2013, 51 patients were diagnosed with LGG before 12 months of age and managed at St. Jude Children's Research Hospital. Twenty-five of the 51 patients received a cognitive assessment (68% male; 6.8 ± 3.3 months at diagnosis; 10.5 ± 4.8 years at latest assessment). Approximately half the patients received radiation therapy (n = 12; aged 4.0 ± 3.0 years at radiation therapy), with a median of 2 chemotherapy regimens (range = 0-5) and 1 tumor directed surgery (range = 0-5). RESULTS: The analyses revealed performance below age expectations on measures of IQ, memory, reading, mathematics, and fine motor functioning as well as parent-report of attention, executive, and adaptive functioning. Following correction for multiple comparisons, a greater number of chemotherapy regimens was associated with lower scores on measures of IQ and mathematics. More tumor directed surgeries and presence of visual field loss were associated with poorer dominant hand fine motor control. Radiation therapy exposure was not associated with decline in neuropsychological performance. CONCLUSIONS: Children diagnosed with LGG in infancy experience substantial neuropsychological deficits. Treatment factors, including number of chemotherapy regimens and tumor directed surgeries, may increase risk for neurodevelopmental disruption and need to be considered in treatment planning.
Authors: Dean W Beebe; M Douglas Ris; F Daniel Armstrong; John Fontanesi; Raymond Mulhern; Emi Holmes; Jeffrey H Wisoff Journal: J Clin Oncol Date: 2005-08-01 Impact factor: 44.544
Authors: Paul G Fisher; Tarik Tihan; Patricia T Goldthwaite; Moody D Wharam; Benjamin S Carson; Jon D Weingart; Michael X Repka; Kenneth J Cohen; Peter C Burger Journal: Pediatr Blood Cancer Date: 2008-08 Impact factor: 3.167
Authors: Christopher D Turner; Christine A Chordas; Cori C Liptak; Celiane Rey-Casserly; Brian L Delaney; Nicole J Ullrich; Liliana C Goumnerova; R Michael Scott; Heather C Begley; William J Fletcher; Xiaopan Yao; Susan Chi; Mark W Kieran Journal: Pediatr Blood Cancer Date: 2009-09 Impact factor: 3.167
Authors: M Douglas Ris; Dean W Beebe; F Daniel Armstrong; John Fontanesi; Emi Holmes; Robert A Sanford; Jeffrey H Wisoff Journal: J Clin Oncol Date: 2008-09-08 Impact factor: 44.544
Authors: Pratiti Bandopadhayay; Guillaume Bergthold; Wendy B London; Liliana C Goumnerova; Andres Morales La Madrid; Karen J Marcus; Dongjing Guo; Nicole J Ullrich; Nathan J Robison; Susan N Chi; Rameen Beroukhim; Mark W Kieran; Peter E Manley Journal: Pediatr Blood Cancer Date: 2014-01-30 Impact factor: 3.167
Authors: Niklas Paul Grusdat; Alexander Stäuber; Marion Tolkmitt; Jens Schnabel; Birgit Schubotz; Henry Schulz Journal: Oncol Res Treat Date: 2021-10-13 Impact factor: 2.825
Authors: Andrew M Heitzer; Kimberly Raghubar; M Douglas Ris; Charles G Minard; Marsha N Gragert; Heather H Stancel; Jessica Orobio; Judy Xue; William Whitehead; M Fatih Okcu; Murali Chintagumpala; Lisa S Kahalley Journal: J Neurosurg Pediatr Date: 2019-12-06 Impact factor: 2.713
Authors: Andrew M Heitzer; Lisa S Kahalley; Charles G Minard; Claire Stafford; David R Grosshans; M Fatih Okcu; Kimberly P Raghubar; Marsha Gragert; Mark McCurdy; Emily H Warren; Jocelyn Gomez; M Douglas Ris; Arnold C Paulino; Murali Chintagumpala Journal: Pediatr Blood Cancer Date: 2021-05-21 Impact factor: 3.838
Authors: Ade Oyefiade; Iris Paltin; Cinzia R De Luca; Kristina K Hardy; David R Grosshans; Murali Chintagumpala; Donald J Mabbott; Lisa S Kahalley Journal: J Clin Oncol Date: 2021-04-22 Impact factor: 50.717
Authors: Yuliang Wang; Anthony Pak Yin Liu; Tatia Mei-Chun Lee; Wilfred Hing Sang Wong; Daniel Yee Tak Fong; Lok Kan Leung; Matthew Ming Kong Shing; Dennis Tak-Loi Ku; Godfrey Chi-Fung Chan; Winnie Wan-Yee Tso Journal: Cancers (Basel) Date: 2022-07-04 Impact factor: 6.575
Authors: Niki Jurbergs; Jennifer L Harman; Ansley E Kenney; Katherine Semenkovich; Andrew E Molnar; Victoria W Willard Journal: Children (Basel) Date: 2019-11-19